Sotera Wireless Names Charlie Alvarez To Lead Sales And Marketing

SAN DIEGO, Sept. 15, 2014  /PRNewswire/ -- Sotera® Wireless today announced that industry veteran Charlie Alvarez has been appointed senior vice president of sales and marketing. Alvarez will lead the Company's strategic initiatives to develop the market for Sotera's ViSi® Mobile System, a wireless, wearable vital signs monitoring platform designed to help hospitals keep clinicians connected to their patients.

In making the announcement, Sotera chief executive officer Tom Watlington cited Alvarez's extensive strategic experience and entrepreneurial track record. "Charlie's grasp of today's healthcare dynamics, combined with success in developing markets, makes him the ideal person to lead the expansion of our ViSi Mobile System business. I believe he will be a key contributor to the acceleration of growth."

"I'm excited to join Sotera, a company that shares its customers' desire to improve quality, safety and satisfaction in healthcare," said Alvarez. "I look forward to helping the Company transform healthcare through the use of continuous patient monitoring."

Alvarez most recently was executive vice president of sales and marketing for SleepMed, Inc., a position he assumed following Watermark Medical's acquisition of SleepMed in 2013. Prior to that, Alvarez was president of Watermark, which he co-founded and grew to $90 million in sales in 2014. He previously held positions at PSS/World Medical, Inc. (now part of McKesson Corporation) and CardioNet.

For more information visit and stay connected with Sotera Wireless via:

ViSi Mobile on Facebook
ViSi Mobile on Twitter
ViSi Mobile on YouTube

About Sotera Wireless
Sotera Wireless, Inc. is a San Diego based medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera's mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient's freedom of movement. More information on the company or its ViSi Mobile System can be obtained at or by sending an email to [email protected]

Sotera® and ViSi Mobile® are registered trademarks of Sotera Wireless, Inc.

SOURCE Sotera Wireless

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.